Read more
List of contents
1. Delivery strategies for immune checkpoint blockade inhibitors
2. Delivery strategies for ex vivo and in vivo T-cell reprogramming
3. Delivery strategies for ex vivo and in vivo NK cell reprogramming
4. Delivery strategies for tumor-associated macrophage reprogramming
5. Reprogramming lymphocytes for tumor immunotherapy
6. Targeting tumor-associated neutrophils in immunotherapy
7. Targeting tumor-associated fibroblast in immunotherapy
8. Oncolytic viral particle delivery
9. Extracellular vesicles (exosomes) in tumor immunotherapy
10. Nucleic acid-based delivery and reprogramming for tumor immuno-oncology
11. CRISPR-based gene editing in cancer immunotherapy
12. Delivery strategies for glioma immunotherapy
13. Delivery strategies for STING agonists
14. Delivery strategies for cancer vaccine and immunoadjuvant
15. Targeted delivery and reprogramming myeloid-derived suppressor cells (MDSC) in cancer
16. Delivery of radio-immunotherapy for solid tumors
17. Delivery of photo-immunotherapy for cancer
18. Local immunotherapy of cancer and metastasis
19. Delivery strategies to overcome tumor immunotherapy resistance
About the author
Mansoor M. Amiji is the Distinguished Professor and Chairman of the Department of Pharmaceutical Sciences at the Bouvé College of Health Sciences at Northeastern University. Dr. Amiji has edited a number of books and is a frequently published author. His research focuses on the synthesis of novel polymeric materials for medical and pharmaceutical applications, drug delivery systems and nanomedical technologies, and his contributions in research advising, grant reviews for various organizations and editorial work for journals are invaluable.Dr. Lara Milane is Assistant Teaching Professor in Biotechnology at the Bouvé College of Health Sciences at Northeastern University. She is interested in Mitochondrial Medicine. She is working on developing nanomedicines for a range of diseases (cancer, neurodegenerative disease, aging) that manipulate mitochondria for therapeutic outcomes. Dr. Milane was trained as a National Cancer Institute/ National Science Foundation Nanomedicine Fellow at Northeastern University, Boston, MA. Dr. Milane is an intuitive cancer biologist with research interests in developing translational nanomedicines that exploit the hallmarks of cancer.
